Cartesian Therapeutics (RNAC) Current Leases (2019 - 2026)

Cartesian Therapeutics (RNAC) has 8 years of Current Leases data on file, last reported at $4.2 million in Q1 2026.

• Current Leases for Q1 2026 came in at $4.2 million, up 13.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (up 13.01% YoY), and the FY2025 annual result was $4.2 million, up 45.6% from the prior year.
• Current Leases grew to $4.2 million in Q1 2026 per RNAC's latest filing, from $4.2 million in the prior quarter.
• Over five years, Current Leases peaked at $4.2 million in Q1 2026 and troughed at $1.1 million in Q1 2022.
• A 5-year average of $2.5 million and a median of $2.2 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2025 and 2026: Current Leases jumped 66.17% in 2025, then gained 13.01% in 2026.
• A 5-year view of Current Leases shows it stood at $1.6 million in 2022, then jumped by 34.7% to $2.2 million in 2023, then soared by 31.63% to $2.9 million in 2024, then jumped by 45.6% to $4.2 million in 2025, then grew by 0.84% to $4.2 million in 2026.
• Business Quant data shows RNAC's Current Leases at $4.2 million in Q1 2026, $4.2 million in Q4 2025, and $3.9 million in Q3 2025.